PFM Health Sciences, LP 13D and 13G filings for Arcus Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:06 pm Sale | 2022-12-31 | 13G | Arcus Biosciences, Inc. RCUS | PFM Health Sciences, LP | 2,703,287 3.700% | -1,229,946 (-31.27%) | Filing |
| 2022-10-17 4:01 pm Purchase | 2022-10-06 | 13G | Arcus Biosciences, Inc. RCUS | PFM Health Sciences, LP | 3,933,233 5.500% | 502,223 (+14.64%) | Filing |
| 2022-02-14 12:38 pm Purchase | 2021-12-31 | 13G | Arcus Biosciences, Inc. RCUS | PFM Health Sciences, LP | 3,431,010 4.900% | 57,550 (+1.71%) | Filing |
| 2021-02-16 4:10 pm Unchanged | 2020-12-31 | 13G | Arcus Biosciences, Inc. RCUS | PFM Health Sciences, LP | 3,373,460 5.200% | 0 (Unchanged) | Filing |
| 2020-11-09 4:01 pm Purchase | 2020-10-29 | 13G | Arcus Biosciences, Inc. RCUS | PFM Health Sciences, LP | 3,373,460 5.200% | 3,373,460 (New Position) | Filing |